Evidence map›Paper›PMID 30892701›Full record

ArticleCancer2019

Noncancer mortality among adolescents and young adults with cancer.

Chelsea Anderson, Jennifer L Lund, Mark A Weaver, William A Wood, Andrew F Olshan, Hazel B Nichols

Abstract read
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Causes of death after surgery among cancer patients: a population-based cohort study.International journal of surgery (London, England) · 2026
    Article
  7. Factors influencing engagement in survivorship care among young adult survivors of hematologic malignancies: a mixed methods report.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023
    Review
  13. Observational
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Chelsea AndersonDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0001-6535-481X
Jennifer L LundDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-1108-0689
Mark A WeaverDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina.
William A WoodDivision of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0001-7439-2543
Andrew F OlshanDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.
Hazel B NicholsDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-0972-1560

Funding

Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
NCI NIH HHS T32 CA057726NICHD NIH HHS P2C HD050924
6 · The paper itself

Abstract

backgroundRelative to the general population, cancer patients and survivors may have an elevated risk of mortality from noncancer causes, such as cardiovascular disease and infections, but few studies have examined rates of noncancer mortality among patients diagnosed as adolescents and young adults (AYAs) (ages 15-39 years).

methodsThe Surveillance, Epidemiology, and End Results database was used to identify AYA patients who were diagnosed with a first malignant cancer between 1973 and 2015. Rates of mortality from noncancer causes among AYAs with cancer were compared with those in the general US population using standardized mortality ratios (SMRs), adjusted for age, sex, race, and calendar year.

resultsAmong 235,541 AYAs with cancer, a total of 12,948 deaths from noncancer causes occurred over 3.1 million total person-years of follow-up. Overall, noncancer mortality was significantly increased among AYAs with cancer relative to the general population (SMR, 1.84; 95% CI, 1.80-1.87). SMRs were particularly elevated for infectious diseases (SMR, 5.13; 95% CI, 4.95-5.32), cardiovascular disease (SMR, 1.55; 95% CI, 1.50-1.60), and renal diseases (SMR, 2.40; 95% CI, 2.12-2.71). These associations persisted for more than 20 years after cancer diagnosis. Cancer types associated with the highest SMRs for all noncancer mortality included leukemias (SMR, 5.26), Hodgkin lymphoma (SMR, 3.12), non-Hodgkin lymphoma (SMR, 6.33), central nervous system tumors (SMR, 3.38), head and neck cancers (SMR, 2.09), and cervical/uterine cancers (SMR, 2.03).

conclusionsAYAs with cancer have an elevated burden of mortality from noncancer causes that persists many years after cancer diagnosis, highlighting the importance of comprehensive, long-term follow-up care for noncancer conditions throughout survivorship.

Indexed as

AdolescentAdultCardiovascular DiseasesCommunicable DiseasesFemaleFollow-Up StudiesHumansKidney DiseasesMaleMiddle AgedNeoplasmsPrognosisSurvival RateTime FactorsYoung Adultadolescents and young adultscancermortalitysurvivorship

Identifiers

PMID30892701
PMCPMC7001100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.